Newbury Pharmaceuticals Q2: A Growing Snowball - Redeye

Redeye provides a research update following the Q2 report published by Newbury yesterday. We make some slight adjustments to our estimates for operational expenditures, investments, and net sales. However, we reiterate our fair value range with a base case valuation of SEK8.5 as our outlook on the case remains positive.

Länk till analysen i sin helhet: https://www.redeye.se/research/892737/newbury-pharmaceuticals-q2-a-growing-snowball?utm_source=finwire&utm_medium=RSS